Foundation Medicine, AstraZeneca ink cancer genomics pact

Cambridge, MA-based Foundation Medicine has inked its ninth industry collaboration on cancer genomics, and it's another marquee player. AstraZeneca ($AZN) will put Foundation Medicine's technology to use in search of discovering genomic alterations that could help direct its R&D efforts. Foundation--a 2012 Fierce 15 company--gains first rights to negotiate on new diagnostics. "This collaboration with Foundation Medicine will help us to identify tumour-specific defects and alterations that can be used for patient segmentation," said AstraZeneca's Susan Galbraith. Release

 

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.